Adeno-associated virus (AAV) is rapidly becoming the go-to biological delivery method for the latest gene therapy breakthroughs. AAV has an efficacy and safety profile that makes it an ideal therapeutic vector—already part of several high-profile drug approvals in both the US and Europe. Yet, with this intensified interest in AAV therapies comes the need to scale-up viral production methods. As such, it’s imperative that successful viral production delivers high titers cost effectively and is scalable. During this webinar session, our presenter will highlight a scalable, high-titer, simplified AAV production in the AAV-MAX helper-free AAV Production System.